https://orcid.org/0000-0002-0024-0958
References
- Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. 2020;15(1):39. doi:10.1186/s13023-020-1320-1
- Liu YX, Zhang J, Nie XL, et al. The effect of topical sirolimus on superficial Kaposiform hemangioendothelioma. Australas J Dermatol. 2021;62(2):e329–e331. doi:10.1111/ajd.13499
- Pan WK, Li P, Guo ZT, et al. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatric Blood Cancer. 2015;62(8):1414–1420. doi:10.1002/pbc.25453
- Wei L, Li L, Xu Z, et al. Comparison of effectiveness of two different doses of propranolol on kaposiform hemangioendothelioma. Front Pediatric. 2022;10:760401. doi:10.3389/fped.2022.760401
- Yu L, Wei L, Ma L, et al. First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol. J Dermatol. 2023;50(4):e123–e124. doi:10.1111/1346-8138.16657
- Zhang X, Yang K, Chen S, et al. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma. J Dermatol. 2019;46(10):898–901. doi:10.1111/1346-8138.15031
- Nic DE, Sadlier M. A kaposiform haemangioendothelioma successfully treated with topical tacrolimus and compression bandaging. Clin Exp Dermatol. 2022;47(10):1870–1871. doi:10.1111/ced.15292